By InvitationNot Applicable

High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia

China44 participantsStarted 2024-03-04

Plain-language summary

The efficacy of B-hydroxy-β-methybutyrate in sarcopenia

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with active Crohn's disease (CD) who visited the Sixth Affiliated Hospital of Sun Yat-sen University between July 2023 and December 2024;
✓. Aged 18-50 years;
✓. Complicated with sarcopenia;
✓. Willing and able to tolerate oral exclusive enteral nutrition (EEN) therapy;
✓. Signed informed consent and able to comply with the study procedures;
✓. Colonic or ileocolonic type CD (SES-CD ≥6; if only terminal ileum is involved, SES-CD ≥4).

✕. Short bowel syndrome;
✕. High-output jejunal fistula;
✕. Severe stress or shock status;
✕. Complete mechanical intestinal obstruction, acute gastrointestinal bleeding, or severe intra-abdominal infection;
✕. Severe hepatic, renal, or cardiac diseases, or malignant tumors;
✕. History of allergy or contraindication to Ensure or HMB;
✕. Persistent severe vomiting or intractable diarrhea;
✕. Congenital disorders of sugar or amino acid metabolism;

muscle strength improvement

Timeframe: Week 4; Week 8

NCT IDNCT07171593

SponsorSixth Affiliated Hospital, Sun Yat-sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-22